Trial Profile
Clinical Study of Apatinib Mesylate Combined With Stereotactic Body Radiation Therapy in the Treatment of Oligometastasis of Breast Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Advanced breast cancer; Cancer metastases
- Focus Therapeutic Use
- 12 Mar 2018 New trial record